New vaccine targets stomach bug that sickens millions
NCT ID NCT05500417
First seen Jan 31, 2026 · Last updated May 22, 2026 · Updated 20 times
Summary
This early-stage trial tested a new vaccine (CJCV2) designed to prevent Campylobacter infection, a common cause of food poisoning. About 60 healthy adults received three different doses of the vaccine, with or without an immune-boosting ingredient called ALFQ. The main goal was to check safety and see how well the vaccine triggers an immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CAMPYLOBACTER INFECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cincinnati Children's Hospital Medical Center Vaccine Research Center
Cincinnati, Ohio, 45229-3039, United States
Conditions
Explore the condition pages connected to this study.